



Emmessar Biotech & Nutrition Ltd.

Registered Office: Plot No.T-3/2, MIDC, Talaja, Raigad Dist., Maharashtra - 410 208.
CIN: L24110MH1992PLC06594229

UNAUDITED FINANCIAL RESULTS (STANDALONE) FOR THE QUARTER ENDED 30TH JUNE 2020

(₹ in lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
		Unaudited	Audited	Audited	Audited
	PART A				
1	Revenue from Operations	29.21	86.04	188.56	339.59
2	Other Income	19.33	37.10	35.37	146.51
	Total Income (1 + 2)	48.54	123.14	223.93	486.10
	PART B				
3	Expenses				
	Cost of material consumed	2.15	87.82	62.97	209.76
	Purchase of Stock-trade	4.80	0.80	12.45	14.22
	Change in Inventories of Finished goods	9.89	(65.39)	33.83	(69.90)
	Employee Benefit Expenses	12.38	12.86	13.63	57.54
	Depreciation & Amortisation of Assets	1.44	1.43	1.45	5.78
	Other Expenditure	15.43	66.50	59.63	168.55
	Total Expenses	46.09	104.02	183.96	385.94
4	Profit / (loss) from Operations before exceptional items & Tax (A-B)	2.45	19.12	39.97	100.16
5	Exceptional items	0.00	26.40	0.00	26.40
6	Profit / (loss) before tax (4 - 5)	2.45	(7.28)	39.97	73.76
7	Tax Expenses				
	1. Current Tax (MAT)	0.00	(16.00)	0.00	(16.00)
	2. Deferred Tax	0.00	2.05	0.00	2.05
	3. MAT Credit available	0.00	15.66	0.00	15.66
	4. Excess/short provision of earlier years	0.61	0.00	0.00	(0.10)
8	Net Profit / (loss) after tax (6 - 7)	3.06	(5.57)	39.97	75.37
9	Other Comprehensive Income	0.00	(0.05)	0.00	0.05
10	Total comprehensive income and Other Comprehensive Income	3.06	(5.62)	39.97	75.42
11	Paid-up Equity Share Capital	499.61	499.61	499.61	499.61
	(Face Value of the share)	10.00	10.00	10.00	10.00
	Earning per Shares				
	1. Basic	0.06	(0.11)	0.80	1.51
	2. Diluted	0.06	(0.11)	0.80	1.51

Notes:

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 10th September 2020 and have been subjected to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
- The Company operates three segments i.e. Healthcare, Fine Chemicals and rent on leasehold land during this quarter.
- Deferred tax & provision for taxation will be calculated annually.
- Rent on immovable property was not received from 01.04.2020 to 17.05.2020 on account of dispute with the lessee, and the same will be accounted for on resolution of dispute with party.
- No Investor Complaint was received for the quarter ended 30th June 2020

Segmentwise Revenue, Results and Capital Employed for the Quarter Ended 30th June 2020

(₹ in lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
		Unaudited	Audited	Audited	Audited
1	Segment Revenue				
a	Healthcare	1.59	2.49	41.96	53.48
b	Fine Chemicals	27.62	83.55	146.60	286.11
c	Rent on Leasehold Land	16.29	33.78	33.78	135.13
d	Others	3.04	3.32	1.59	11.38
	Total:	48.54	123.14	223.93	486.10
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00
	Net Sales / Income from Operations	48.54	123.14	223.93	486.10
2	Segment Results (Profit / Loss) tax				
a	Healthcare	0.64	1.82	26.72	34.94
b	Fine Chemicals	3.85	0.69	7.38	(11.16)
c	Rent on Leasehold Land	16.06	33.78	33.55	135.13
d	Others	3.04	3.32	1.59	11.38
	Total:	23.59	39.61	69.24	170.29
	Less:				
	Interest	0.00	0.00	0.00	0.00
	Other Unallocable Expenditure (Net off)	21.14	20.49	29.27	70.13
	Total Profit before Tax & Exceptional items	2.45	19.12	39.97	100.16
3	Capital Employed (Segment Assets - Segment Liabilities)				
a	Healthcare	11.12	8.23	7.87	8.23
b	Fine Chemicals	93.42	28.95	71.73	28.95
c	Leasehold Land	1.85	2.08	2.78	2.08
d	Others	272.78	287.74	172.84	287.74
	Total:	379.17	326.99	255.22	326.99

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on September 10th, 2020

Mumbai
10-Sep-2020

By order of the Board
MSR Ayyangar
Managing Director